Data protection Impressum

Covid-19

GeNeuro‘s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments

5 February 2024

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.

Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings

16 October 2023

Revolutionary mRNA vaccine against melanoma to be tested in Geneva

13 June 2023

Chinese vaccine manufacturer CanSino Biologics sets up shop in Geneva to launch its inhaled Covid vaccine

10 October 2022

Improved COVID-19 vector vaccine candidate

4 August 2022

Predictive analytics start-up Kido Dynamics raises EUR 1.9 million

30 November 2021

The University of Bern has developed a non-contagious SARS-CoV-2 model

26 October 2021

CHUV and EPFL discover a highly potent antibody against SARS-CoV-2

13 October 2021

A serological test to assess immunity against SARS-CoV-2

21 July 2021

Switzerland’s Spiez Laboratory at the heart of WHO’s BioHub system

1 June 2021

1 2 3 4 5 6